Virus-Like Particle Conjugates

Abstract

This invention is directed to immunogenic composition, conjugates, virus-like particles (VLP) compositions, vaccines and methods directed to the treatment and/or prevent of infection by Human Papillomavirus.

Claims

1. An immunogenic composition comprising virus-like particles (VLPs) obtained or derived from L1 and/or L2 proteins of Human papilloma virus (HPV), conjugated with a spacer arm and a carrier protein.

2. The immunogenic composition of claim 1, wherein the HPV comprises serotype 6, 11, 16, 18, 31, 33, 45, 52, and/or 58.

3. The immunogenic composition of claim 1, wherein the spacer arm comprises a hetero- or homo-bifunctional or multifunctional spacer arm.

4. The immunogenic composition of claim 1, wherein the spacer arm comprises NH.sub.2-PEG-NH.sub.2/NHS, NHS/NH.sub.2-PEG-COOH, Mal-PEG-NH.sub.2, Mal-PEG-NHS, CHO-PEG-CHO, SH-PEG-NH.sub.2, ADH, HZ-PEG-HZ, SMPH, SMCC, 4-Arm-PEG-NH.sub.2.

5. The immunogenic composition of claim 1, wherein the carrier protein comprises tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), N. meningitidis protein PorB, RSV virus proteins, B. pertussis proteins, pertussis toxoid (PT), adenylate cyclase toxin (ACT), 69 KDa protein, Human Papilloma viral protein antigens, Human Papilloma virus VLP forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, derivatives of HBsAg, and/or combinations thereof.

6. The immunogenic composition of claim 1, further comprising an adjuvant.

7. The immunogenic composition of claim 6, wherein the adjuvant comprises aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, TLR ligands, and/or a potent TLR4/7/8/9 agonists.

8. The immunogenic composition of claim 7, wherein the aluminum salt is selected from the group consisting of aluminum phosphate, aluminum sulfate and/or aluminum hydroxide.

9. The immunogenic composition of claim 1, wherein the VLP is obtained or derived from HPV L1 protein or HPV L2 protein and the carrier protein is CRM197.

10. The immunogenic composition of claim 1, wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 16 and/or 18, and the carrier protein is CRM197.

11. The immunogenic composition of claim 1, wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 6 and/or 11, and the carrier protein is CRM197.

12. The immunogenic composition of claim 1, wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 31 and/or 33, and the carrier protein is CRM197.

13. The immunogenic composition of claim 1, wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 45 and/or 52, and the carrier protein is CRM197.

14. The immunogenic composition of claim 1, wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 58, and the carrier protein is CRM197.

15. The immunogenic composition of claim 1, wherein the VLPs comprise L1 protein conjugated to L2 protein, and the carrier protein is CRM197.

16. The immunogenic composition of claim 1, wherein administration to a patient boosts the efficacy of a conventional vaccine.

17. An immunogenic composition comprising virus-like particles (VLPs) obtained or derived from L1 protein of Human papilloma virus (HPV), conjugated with a spacer arm and a carrier protein, wherein: the HPV comprises serotype 6, 11, 16, 18, 31, 33, 45, 52, and/or 58; the spacer arm comprises a hetero-bifunctional spacer arm; and the carrier protein comprises tetanus toxoid or diphtheria toxoid.

18. The immunogenic composition of claim 17, further comprising an adjuvant.

19. An immunogenic composition comprising virus-like particles (VLPs) obtained or derived from L2 protein of Human papilloma virus (HPV), conjugated with a spacer arm and a carrier protein, wherein: the HPV comprises serotype 6, 11, 16, 18, 31, 33, 45, 52, and/or 58; the spacer arm comprises a hetero-bifunctional spacer arm; and the carrier protein comprises tetanus toxoid or diphtheria toxoid.

20. The immunogenic composition of claim 19, further comprising an adjuvant.

Description

DESCRIPTION OF THE FIGURES

[0017] FIG. 1 Bi-functional spacer arm for activation of CRM197; Mal-Maleimide, NHS-Succinimide, PEG-Polyethylene glycol derivatives, ADH-Adipic acid di-hydrazide, HZ-hydrazide, 1k and 3K-Mn 1000 and 3500,

[0018] FIG. 2 Schematic of the mechanism of action of VLP.

[0019] FIG. 3 Schematic of conjugation of VLP with carrier protein CRM197 with a spacer arm.

[0020] FIG. 4 Schematic of VLP-CRM-VLP conjugate, where HPV VLP L116 type is first conjugates according to scheme 2, followed by VLP L1 18 type is conjugated with VLP L1-CRM197 conjugate.

DESCRIPTION OF THE INVENTION

[0021] It was surprisingly discovered that a conjugate could be made that provides HPV immunity equivalent to conventional HPV vaccines and with only two doses and with reduced antigens per dose making. The consequence is a vaccine that is five-fold less expensive than conventional vaccines and requires a lower dose making the vaccine more practical and more widely available.

[0022] The disclosure is directed to a pharmaceutical conjugate vaccine composition for a human cervical cancer, comprising of virus-like particles preferably derived from L1 HPV clones, conjugated using a spacer arm with a carrier protein, preferably CRM197 and CRM197-like proteins, used in conjugate vaccines and one L2-HPV VLP, and a pharmaceutically acceptable aluminum adjuvant (or non-aluminum adjuvant) and suitable buffer. The conjugate combination comprises combination of L1 and L2 VLPs for the regions where the prevalent infections of those serotypes exist.

[0023] The disclosure is directed to immunogenic compositions comprising virus-like particles (VLPs) obtained or derived from L1 and/or L2 proteins of Human papilloma virus (HPV), conjugated with a spacer arm and a carrier protein. Preferably the HPV comprises serotype 6, 11, 16, 18, 31, 33, 45, 52, and/or 58. Preferably the spacer arm comprises a hetero- or homo-bifunctional or multifunctional spacer arm, or in particular, comprises NH.sub.2-PEG-NH.sub.2/NHS, NHS/NH.sub.2-PEG-COOH, Mal-PEG-NH.sub.2, Mal-PEG-NHS, CHO-PEG-CHO, SH-PEG-NH.sub.2, ADH, HZ-PEG-HZ, SMPH, SMCC, 4-Arm-PEG-NH.sub.2. Preferably the carrier protein comprises tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), N. meningitidis protein PorB, RSV virus proteins, B. pertussis proteins, pertussis toxoid (PT), adenylate cyclase toxin (ACT), 69 KDa protein, Human Papilloma viral protein antigens, Human Papilloma virus VLP forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, derivatives of HBsAg, and/or combinations thereof. Preferably the immunogenic composition comprises an adjuvant, and preferably the adjuvant comprises aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, TLR ligands, and/or a potent TLR4/7/8/9 agonists. Preferred aluminum salts include one or more of aluminum phosphate, aluminum sulfate and/or aluminum hydroxide. Preferably the immunogenic composition, when administered to a patient, boosts the efficacy of a conventional vaccine.

[0024] This disclosure comprises an immunogenic composition as described herein wherein the VLP is obtained or derived from HPV L1 protein or HPV L2 protein and the carrier protein is CRM197; wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 16 and/or 18, and the carrier protein is CRM197; wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 6 and/or 11, and the carrier protein is CRM197; wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 31 and/or 33, and the carrier protein is CRM197; wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 45 and/or 52, and the carrier protein is CRM197; wherein the VLPs are bi-valent L1 VLP conjugates, the HPV is serotype 58, and the carrier protein is CRM197; and wherein the VLPs comprise L1 protein conjugated to L2 protein, and the carrier protein is CRM197.

[0025] The present disclosure includes formulation for at least 9-, 10- or higher valent VLP conjugate vaccine which reduces the necessary dose (8-10 μg/dose of individual VLPs compared with 20-40 μg dose used in Gardasil, Merck or Cerverix, GSK) adsorbed in aluminum phosphate or aluminum hydroxide or other suitable TLR7/8/9 or TLR 4 adjuvants. Examples of VLP-protein conjugates formulations:

[0026] VLP1-CRM197-VLP2 (4 and 9-valent L1, 10-valent with L2);

[0027] HPV-VLP/CRM197 (monovalent conjugates); and

[0028] VLP1-CRM197-VLP2 (4 and 9-valent L1, 10-valent with L2).

[0029] Conjugates include conjugation with HBHBSAg as, for example, HBSAg-VLP/CRM197.

[0030] The present disclosure is directed to L1 VLP-based 9 valent vaccine candidates as well as addition of L2-VLP based 10 valent vaccines. Four sets of two L1 VLPs are chemically conjugated using a bi-functional spacer arm with a carrier protein (e.g., CRM197 from E. coli) and one L1-VLPs conjugated with L2 VLP. L1 and L2-based VLP conjugates can be in general structurally represented as:

[0031] L1-XX-VLP-spacer arm-CRM197 L1-XX-VLP

[0032] L1-XX-VLP-spacer arm-CRM197 L2-VLP

[0033] XX can be any L1 VLP

[0034] Examples included are,

[0035] L1 VLP16-Spacer arm-CRM197-L1 VLP18

[0036] L1 VLP6-spacer arm-CRM197-L1 VLP11

[0037] L1 VLP31-spacer arm-CRM197-L1 VLP33

[0038] L1 VLP45-spacer arm-CRM197-L1 VLP52

[0039] L1 VLP58-spacer arm-CRM197-L2 VLP

[0040] The following examples illustrate embodiments of the invention but should not be viewed as limiting the scope of the invention.

EXAMPLES

Example 1

Expression and Purification of Recombinant HPV L1 and L2 VLP in Yeast

[0041] L1 protein form all 9 serotypes and L2 protein are expressed in Yeast Hansenula polymorpha. Fermentation cycle: ˜120 hrs. Expression induced by Methanol using H.P. promoter. The L1 and L2 protein were extracted using yeast cell wall lytic enzymes Zymolase, followed by Benzonase treatment for nucleic acid removal. The extraction step was carried out in TRIS buffer, 20-50 mM, pH 8.5-9.5. The clarified extract (concentration 1 mg/ml, with the L1 protein 150-200 ug/ml), were applied to a cation-exchange chromatography, followed by gel filtration chromatography. In this step, the di-assemble was utilized and assemble step causing the VLP's to assemble in the right configuration and stable molecules. This is confirmed using TEM, The VLPs were stabilized using appropriate buffer. Finally, VLPS are Concentrated using ultrafiltration.

[0042] All serotypes L1 VLPs and L2 VLP purification yields are in the region of 7-15% of cell extract, the purified VLPs are 98-99% homogeneous purity. FIG. 2 describes the process flow chart showing the experimental procedures used to purify L1 and L2 HPV serotypes VLPs. All purified VLPs were checked for amino acid sequence, free thiols and lysine's are used with the purpose of stability and site availability for chemical conjugation with carrier proteins.

Example 2

Chemical Conjugation Procedure of L1 and L2 VLPs with CRM197

[0043] Chemical conjugation of VLPs are accomplished by the use of chemical cross-linkers, moreover, various conjugation strategies used, for example, use pegylated homo or hetero-bifunctional conjugation reagents having same or two evident reactive groups which can bond to different and distinct functional targets, one on the antigen and the other on the VLP (typically amines or sulfhydryl residues).

Example 3

Activation of CRM197 Using Bi-Functional Spacer Arm

[0044] Carrier protein CRM197 activation using pegylated and non-homo or hetero-bifunctional spacer arm. CRM-197 (10 mg/ml) was dissolved in activation buffer, followed by bi-functional spacer arm (see FIG. 1) addition in presence of PB or MES buffer, 80 mM-200 mM, pH 5.8-6.2. Functionalized CRM197 was purified using 10-30 KD TFF cassettes (FIG. 2).

Example 4

Conjugation Process of Functionalized CRM197 to L1 VLP

[0045] The basic method steps of conjugation as follows: [0046] 1. Chemical conjugation between L1 or L2-VLPs and carrier protein CRM197 (FIG. 3). [0047] 2. Evaluation of HPV VLPs integrity after conjugation with CRM197. [0048] 3. Analytical characterization of HPV L1 and L2 VLPs and chemically conjugated bi-valent unimolecular or bi-valent VLPS. [0049] 4. Formulation of VLP-protein conjugates. [0050] 5. Comparison of Immunogenicity with Gardasil-9. [0051] 6. Stability study of VLP conjugates.

[0052] Examples of conjugates formed include:

[0053] I. Conjugation process of L116 HPV-VLP to functionalized CRM197.

[0054] II. Conjugation process of L1 HPV 16 VLP-CRM to L1-HPV 18 VLP (FIG. 4),

[0055] III. Conjugation process of L1 58 HPV-VLP-CRM197-L2 HPV VLP.

[0056] Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. All references cited herein, including all publications, U.S. and foreign patents and patent applications, are specifically and entirely incorporated by reference. It is intended that the specification and examples be considered exemplary only with the true scope and spirit of the invention indicated by the following claims. Furthermore, the term “comprising of” includes the terms “consisting of” and “consisting essentially of.”